A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Bimekizumab (Primary) ; Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB Biopharma
- 04 Apr 2018 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
- 04 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Sep 2018.
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.